These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
144 related items for PubMed ID: 14959848
1. Immunological effects of interferon-alpha on chronic myelogenous leukemia. de Castro FA, Palma PV, Morais FR, Simões BP, Carvalho PV, Ismael SJ, Lima CP, Voltarelli JC. Leuk Lymphoma; 2003 Dec; 44(12):2061-7. PubMed ID: 14959848 [Abstract] [Full Text] [Related]
2. Immunological effects of donor lymphocyte infusion in patients with chronic myelogenous leukemia relapsing after bone marrow transplantation. Castro FA, Palma PV, Morais FR, Voltarelli JC. Braz J Med Biol Res; 2004 Feb; 37(2):201-6. PubMed ID: 14762574 [Abstract] [Full Text] [Related]
3. Phenotypic and functional characterization of the host immune compartment of chronic myeloid leukaemia patients in complete haematological remission. Guarini A, Breccia M, Montefusco E, Petti MC, Zepparoni A, Vitale A, Foa R. Br J Haematol; 2001 Apr; 113(1):136-42. PubMed ID: 11328293 [Abstract] [Full Text] [Related]
4. Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile. Kreutzman A, Rohon P, Faber E, Indrak K, Juvonen V, Kairisto V, Voglová J, Sinisalo M, Flochová E, Vakkila J, Arstila P, Porkka K, Mustjoki S. PLoS One; 2011 Apr; 6(8):e23022. PubMed ID: 21857985 [Abstract] [Full Text] [Related]
5. Activation of autologous lymphocytes of patients with chronic myelogenous leukemia in the chronic phase with cytokines and CD3 monoclonal antibody results in bcr/abl- blood leukocyte cultures as determined by reverse transcriptase-polymerase chain reaction. Krackhardt A, Maurer J, Thiel E, Notter M. Exp Hematol; 1998 Dec; 26(13):1265-70. PubMed ID: 9845383 [Abstract] [Full Text] [Related]
13. Expression of interferon regulatory factor 4 in chronic myeloid leukemia: correlation with response to interferon alfa therapy. Schmidt M, Hochhaus A, König-Merediz SA, Brendel C, Proba J, Hoppe GJ, Wittig B, Ehninger G, Hehlmann R, Neubauer A. J Clin Oncol; 2000 Oct 01; 18(19):3331-8. PubMed ID: 11013272 [Abstract] [Full Text] [Related]
14. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. Paschka P, Müller MC, Merx K, Kreil S, Schoch C, Lahaye T, Weisser A, Petzold A, König H, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A. Leukemia; 2003 Sep 01; 17(9):1687-94. PubMed ID: 12970765 [Abstract] [Full Text] [Related]
15. Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alpha. Pawelec G, Da Silva P, Max H, Kalbacher H, Schmidt H, Bruserud O, Zügel U, Baier W, Rehbein A, Pohla H. Leuk Lymphoma; 1995 Aug 01; 18(5-6):471-8. PubMed ID: 8528055 [Abstract] [Full Text] [Related]